LOWSeeking AlphaUnverifiedUnpublished

Fact-check: Real-time X posts from March 3-4, 2026, actively discuss ImmunityBio's Q4 2025 earnings call, including specific details like FY 2025 revenue of $113M and Q4 $38.3M, confirming the event occurred. Seeking Alpha published the official transcript dated March 3, 2026, matching company announcements. Fully consistent with current reporting on X and web sources.

ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript

immunitybioibrxearningsbiotechpharmaceuticalsfinancial-resultsunited-states

ImmunityBio, Inc. (ticker: IBRX) held its Q4 2025 earnings call, presenting the company's financial results and operational updates for the quarter. The transcript covers executive commentary on revenue, expenses, and pipeline developments for the biopharmaceutical company.

ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript

[Sources]

Fact-check sources